{"id":27814,"date":"2026-11-13T10:19:30","date_gmt":"2026-11-13T08:19:30","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/"},"modified":"2026-11-16T16:13:14","modified_gmt":"2026-11-16T14:13:14","slug":"trasferire-un-processo-atmp-a-un-nuovo-cdmo","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/","title":{"rendered":"Transferring an ATMP Manufacturing Process to a New CDMO"},"content":{"rendered":"<p>Completing an initial manufacturing run at a new site answers a practical question: has the receiving team successfully executed the process? From that point onward, the sponsor can examine the materials produced, compare the resulting data with historical data, and assess any differences introduced by the transfer. This is where distinguishing successful process execution from the evidence required to formally close the technology transfer becomes particularly important.<\/p>\n<p>On <strong>5 November 2026<\/strong>, Norwegian company <strong>Zelluna<\/strong> announced the completion of its first manufacturing run at a new CDMO for its TCR-NK cell therapy platform. Analytical and functional characterization of the resulting product was still ongoing. The previous day, the company had announced <strong>NOK 15.6 million in funding<\/strong> from the Research Council of Norway to further develop its manufacturing capabilities [1, 2]. The publicly disclosed milestone therefore concerns the completion of the initial manufacturing run; the company&#8217;s update does not report a final outcome of the comparability assessment.<\/p>\n<h2>Technology transfer starts with the differences between sites<\/h2>\n<p>The receiving site must be able to reconstruct the process using the documentation, data, and experience of the team that developed it. A manufacturing instruction may specify a maximum hold time or a criterion for proceeding to the next step. However, applying that instruction in a different setting requires an understanding of the data supporting it and what happens to the product as the specified limit is approached.<\/p>\n<p>A meaningful assessment begins with the actual differences between the sites: equipment configuration, material preparation procedures, intervals between operations, sampling points, and storage conditions. Even when both sites use the same equipment models, the operational sequence may differ. A different arrangement of activities may extend the interval between two process steps or change how samples are transferred to the laboratory.<\/p>\n<p>For each difference, the sponsor and CDMO should determine which product attributes could be affected, what supporting evidence is already available, and what additional data need to be collected during the transfer. This assessment also helps identify which operations require direct observation and hands-on support. The objective is to ensure that the receiving site can recognize unexpected conditions and document how they were managed, even without the presence of the original process development team.<\/p>\n<h2>Analytical method transfer is a separate process<\/h2>\n<p>If the laboratory also changes, a difference in results may reflect a change in the product, the measurement system, or both. Before attributing the difference to the manufacturing process at the new site, it is necessary to establish how comparable the results generated by the two laboratories are. Relevant factors include sample preparation, reagents and reference materials, system suitability criteria, and data processing procedures.<\/p>\n<p>For example, consider a receiving laboratory that consistently measures lower functional activity. Testing common samples, where technically feasible, can help determine whether the discrepancy is already present when the same material is analyzed. If an interlaboratory difference is identified, its underlying cause must be clarified before using those results to assess the impact of the site change. Conversely, if results obtained from common samples are consistent, the investigation can focus more specifically on the manufacturing process and sample handling.<\/p>\n<p>This is where analytical method transfer intersects with the potency strategy: the method must be fit for the decision it is intended to support. During technology transfer, the method must not only measure a relevant biological activity but also generate sufficiently informative data to distinguish analytical variability from a potential change in the product. <a href=\"https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130.pdf?utm_source=chatgpt.com\">ICH Q2(R2)<\/a> provides the general framework for analytical procedure validation [3]. The comparability assessment, in turn, requires a study design tailored to the specific product and manufacturing change [4].<\/p>\n<h2>Comparability and specifications address different questions<\/h2>\n<p>The fact that a batch manufactured at the new site meets its specifications is an important finding. However, assessing the impact of the transfer also requires comparing the product&#8217;s profile before and after the change. A product attribute may shift relative to historical experience while remaining within release limits. Such a shift must be interpreted in the context of variability associated with the analytical method, starting materials, and manufacturing process.<\/p>\n<p>For ATMPs, the EMA <em>reflection paper<\/em> on comparability addresses manufacturing changes and the introduction of new manufacturing sites [4]. In practice, the comparability plan should clearly identify the batches or materials selected for comparison, the attributes to be assessed, and the rationale for considering the analytical methods capable of detecting relevant differences. Depending on the product and associated risks, the comparison may include identity, cellular composition, viability, purity, and functional activity. The selection should be justified: a broader panel of tests is useful only if it provides additional information about the differences that the transfer could introduce.<\/p>\n<p>The basis for comparison also needs to be examined. If historical batches were manufactured using different starting materials or characterized at different stages of development, the protocol should explain how these factors will be accounted for. Defining in advance how deviations from historical data will be interpreted helps prevent acceptance criteria from being established retrospectively, after the results are known.<\/p>\n<h2>Responsibilities to define before the first manufacturing run<\/h2>\n<p>The agreement between the sponsor and the CDMO must make the transfer plan operational. Who decides whether a change introduced by the receiving site can be accepted? Who leads an investigation if a discrepancy involves both the manufacturing process and the laboratory? What data must be accessible to the sponsor to reconstruct the rationale behind a decision and support it in the regulatory dossier? These questions need to be resolved before the first unexpected event occurs.<\/p>\n<p>The technology transfer protocol and quality agreement can translate these questions into clearly defined, verifiable responsibilities: which documents and data must be shared, the timelines for reporting deviations, who approves changes, and how completion of each transfer stage is determined. The EU GMP guidelines specific to ATMPs provide the regulatory framework for outsourced activities [5].<\/p>\n<p>Following the first manufacturing run, it is therefore useful to make three separate assessments: <strong>which operations the new site has demonstrated it can perform; which analytical results can already be meaningfully interpreted; and what additional evidence is needed to assess comparability<\/strong>. These assessments may be completed at different times. Keeping them distinct makes it possible to acknowledge manufacturing progress while explaining, with equal precision, what remains to be demonstrated.<\/p>\n<h3>References:<\/h3>\n<ol start=\"1\">\n<li><strong>Zelluna.<\/strong> <a href=\"https:\/\/zelluna.com\/investors\/news\/zelluna-asa-third-quarter-2026-results?\" target=\"_blank\" rel=\"noopener\"><em>Third Quarter 2026 results<\/em><\/a>, 5 November 2026.<\/li>\n<li><strong>Zelluna.<\/strong> <a href=\"https:\/\/zelluna.com\/investors\/news\/zelluna-asa-awarded-nok-15-6-million-research-council-of-norway-grant-to-further-advance-tcr-nk-manufacturing?\" target=\"_blank\" rel=\"noopener\"><em>Zelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturing<\/em><\/a>, 4 November 2026.<\/li>\n<li><strong>ICH.<\/strong> <a href=\"https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130.pdf\"><em>Q2(R2) \u2013 Validation of Analytical Procedures<\/em><\/a>, final versione, 2023.<\/li>\n<li><strong>EMA.<\/strong> <a href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/guidelines-relevant-advanced-therapy-medicinal-products\"><em>Comparability considerations for advanced therapy medicinal products (ATMPs)<\/em><\/a>, <em>reflection paper<\/em>.<\/li>\n<li><strong>Commissione europea.<\/strong> <a href=\"https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en\"><em>EudraLex Volume 4 \u2013 Good Manufacturing Practice guidelines<\/em><\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Zelluna\u2019s first manufacturing run at a new CDMO provides an opportunity to distinguish between process transfer, analytical method transfer, and comparability assessment for ATMPs. What evidence is needed after the first batch?<\/p>\n","protected":false},"author":32,"featured_media":27769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[769,1101],"tags":[],"class_list":["post-27814","post","type-post","status-publish","format-standard","has-post-thumbnail","category-biodrugs-atmp-en","category-highlights-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-13T08:19:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T14:13:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/#\\\/schema\\\/person\\\/d8e18fc21ef62441a6eb17c2dcedb8d9\"},\"headline\":\"Transferring an ATMP Manufacturing Process to a New CDMO\",\"datePublished\":\"2026-11-13T08:19:30+00:00\",\"dateModified\":\"2026-11-16T14:13:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/makingpharmaindustry.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/ATMP-E-CDMO.png\",\"articleSection\":[\"BioDrugs &amp; ATMP\",\"HIGHLIGHTS\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/\",\"url\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/\",\"name\":\"Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/makingpharmaindustry.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/ATMP-E-CDMO.png\",\"datePublished\":\"2026-11-13T08:19:30+00:00\",\"dateModified\":\"2026-11-16T14:13:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/#\\\/schema\\\/person\\\/d8e18fc21ef62441a6eb17c2dcedb8d9\"},\"description\":\"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/makingpharmaindustry.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/ATMP-E-CDMO.png\",\"contentUrl\":\"https:\\\/\\\/makingpharmaindustry.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/ATMP-E-CDMO.png\",\"width\":1672,\"height\":941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/biodrugs-atmp-en\\\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transferring an ATMP Manufacturing Process to a New CDMO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/#\\\/schema\\\/person\\\/d8e18fc21ef62441a6eb17c2dcedb8d9\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\\\/\\\/makingpharmaindustry.it\\\/en\\\/author\\\/valentina-parrella\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry","description":"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/","og_locale":"en_US","og_type":"article","og_title":"Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry","og_description":"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.","og_url":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2026-11-13T08:19:30+00:00","article_modified_time":"2026-11-16T14:13:14+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO-1024x576.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/d8e18fc21ef62441a6eb17c2dcedb8d9"},"headline":"Transferring an ATMP Manufacturing Process to a New CDMO","datePublished":"2026-11-13T08:19:30+00:00","dateModified":"2026-11-16T14:13:14+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/"},"wordCount":1093,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO.png","articleSection":["BioDrugs &amp; ATMP","HIGHLIGHTS"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/","url":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/","name":"Transferring an ATMP Manufacturing Process to a New CDMO - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO.png","datePublished":"2026-11-13T08:19:30+00:00","dateModified":"2026-11-16T14:13:14+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/d8e18fc21ef62441a6eb17c2dcedb8d9"},"description":"Il caso Zelluna mostra quali evidenze servono dopo il primo lotto ATMP presso un nuovo CDMO, dal trasferimento dei metodi alla comparabilit\u00e0.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/11\/ATMP-E-CDMO.png","width":1672,"height":941},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/biodrugs-atmp-en\/trasferire-un-processo-atmp-a-un-nuovo-cdmo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Transferring an ATMP Manufacturing Process to a New CDMO"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/d8e18fc21ef62441a6eb17c2dcedb8d9","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/27814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=27814"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/27814\/revisions"}],"predecessor-version":[{"id":27816,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/27814\/revisions\/27816"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/27769"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=27814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=27814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=27814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}